189 related articles for article (PubMed ID: 28642484)
21. Silencing of miR-193a-5p increases the chemosensitivity of prostate cancer cells to docetaxel.
Yang Z; Chen JS; Wen JK; Gao HT; Zheng B; Qu CB; Liu KL; Zhang ML; Gu JF; Li JD; Zhang YP; Li W; Wang XL; Zhang Y
J Exp Clin Cancer Res; 2017 Dec; 36(1):178. PubMed ID: 29216925
[TBL] [Abstract][Full Text] [Related]
22. Androgen-induced miR-27A acted as a tumor suppressor by targeting MAP2K4 and mediated prostate cancer progression.
Wan X; Huang W; Yang S; Zhang Y; Zhang P; Kong Z; Li T; Wu H; Jing F; Li Y
Int J Biochem Cell Biol; 2016 Oct; 79():249-260. PubMed ID: 27594411
[TBL] [Abstract][Full Text] [Related]
23. miR-302/367/LATS2/YAP pathway is essential for prostate tumor-propagating cells and promotes the development of castration resistance.
Guo Y; Cui J; Ji Z; Cheng C; Zhang K; Zhang C; Chu M; Zhao Q; Yu Z; Zhang Y; Fang YX; Gao WQ; Zhu HH
Oncogene; 2017 Nov; 36(45):6336-6347. PubMed ID: 28745315
[TBL] [Abstract][Full Text] [Related]
24. MiR-1247-5p is overexpressed in castration resistant prostate cancer and targets MYCBP2.
Scaravilli M; Porkka KP; Brofeldt A; Annala M; Tammela TL; Jenster GW; Nykter M; Visakorpi T
Prostate; 2015 Jun; 75(8):798-805. PubMed ID: 25731699
[TBL] [Abstract][Full Text] [Related]
25. lncRNA HOXD-AS1 Regulates Proliferation and Chemo-Resistance of Castration-Resistant Prostate Cancer via Recruiting WDR5.
Gu P; Chen X; Xie R; Han J; Xie W; Wang B; Dong W; Chen C; Yang M; Jiang J; Chen Z; Huang J; Lin T
Mol Ther; 2017 Aug; 25(8):1959-1973. PubMed ID: 28487115
[TBL] [Abstract][Full Text] [Related]
26. Dysregulation of miR-212 Promotes Castration Resistance through hnRNPH1-Mediated Regulation of AR and AR-V7: Implications for Racial Disparity of Prostate Cancer.
Yang Y; Jia D; Kim H; Abd Elmageed ZY; Datta A; Davis R; Srivastav S; Moroz K; Crawford BE; Moparty K; Thomas R; Hudson RS; Ambs S; Abdel-Mageed AB
Clin Cancer Res; 2016 Apr; 22(7):1744-56. PubMed ID: 26553749
[TBL] [Abstract][Full Text] [Related]
27. Galectin-3 Is Implicated in Tumor Progression and Resistance to Anti-androgen Drug Through Regulation of Androgen Receptor Signaling in Prostate Cancer.
Dondoo TO; Fukumori T; Daizumoto K; Fukawa T; Kohzuki M; Kowada M; Kusuhara Y; Mori H; Nakatsuji H; Takahashi M; Kanayama HO
Anticancer Res; 2017 Jan; 37(1):125-134. PubMed ID: 28011482
[TBL] [Abstract][Full Text] [Related]
28. Micro-ribonucleic acid expression signature of metastatic castration-resistant prostate cancer: Regulation of NCAPH by antitumor miR-199a/b-3p.
Arai T; Kojima S; Yamada Y; Sugawara S; Kato M; Yamazaki K; Naya Y; Ichikawa T; Seki N
Int J Urol; 2019 Apr; 26(4):506-520. PubMed ID: 30818424
[TBL] [Abstract][Full Text] [Related]
29. Secretory leukocyte protease inhibitor is a survival and proliferation factor for castration-resistant prostate cancer.
Zheng D; Gui B; Gray KP; Tinay I; Rafiei S; Huang Q; Sweeney CJ; Kibel AS; Jia L
Oncogene; 2016 Sep; 35(36):4807-15. PubMed ID: 26876202
[TBL] [Abstract][Full Text] [Related]
30. Comprehensive proteomic profiling identifies the androgen receptor axis and other signaling pathways as targets of microRNAs suppressed in metastatic prostate cancer.
Coarfa C; Fiskus W; Eedunuri VK; Rajapakshe K; Foley C; Chew SA; Shah SS; Geng C; Shou J; Mohamed JS; O'Malley BW; Mitsiades N
Oncogene; 2016 May; 35(18):2345-56. PubMed ID: 26364608
[TBL] [Abstract][Full Text] [Related]
31. Targeting Castration-Resistant Prostate Cancer Using Mesenchymal Stem Cell Exosomes for Therapeutic MicroRNA-let-7c Delivery.
Kurniawati I; Liu MC; Hsieh CL; Do AD; Sung SY
Front Biosci (Landmark Ed); 2022 Sep; 27(9):256. PubMed ID: 36224011
[TBL] [Abstract][Full Text] [Related]
32. N-Myc promotes therapeutic resistance development of neuroendocrine prostate cancer by differentially regulating miR-421/ATM pathway.
Yin Y; Xu L; Chang Y; Zeng T; Chen X; Wang A; Groth J; Foo WC; Liang C; Hu H; Huang J
Mol Cancer; 2019 Jan; 18(1):11. PubMed ID: 30657058
[TBL] [Abstract][Full Text] [Related]
33. Pre-existing Castration-resistant Prostate Cancer-like Cells in Primary Prostate Cancer Promote Resistance to Hormonal Therapy.
Cheng Q; Butler W; Zhou Y; Zhang H; Tang L; Perkinson K; Chen X; Jiang XS; McCall SJ; Inman BA; Huang J
Eur Urol; 2022 May; 81(5):446-455. PubMed ID: 35058087
[TBL] [Abstract][Full Text] [Related]
34. MicroRNA-23b and microRNA-27b plus flutamide treatment enhances apoptosis rate and decreases CCNG1 expression in a castration-resistant prostate cancer cell line.
Pimenta RC; Viana NI; Amaral GQ; Park R; Morais DR; Pontes J; Guimaraes VR; Camargo JA; Leite KR; Nahas WC; Srougi M; Reis ST
Tumour Biol; 2018 Nov; 40(11):1010428318803011. PubMed ID: 30400755
[TBL] [Abstract][Full Text] [Related]
35. miR-103a-2-5p/miR-30c-1-3p inhibits the progression of prostate cancer resistance to androgen ablation therapy via targeting androgen receptor variant 7.
Chen W; Yao G; Zhou K
J Cell Biochem; 2019 Aug; 120(8):14055-14064. PubMed ID: 30963631
[TBL] [Abstract][Full Text] [Related]
36. Anti-androgen therapy induces transcriptomic reprogramming in metastatic castration-resistant prostate cancer in a murine model.
Zhao Y; Peng X; Baldwin H; Zhang C; Liu Z; Lu X
Biochim Biophys Acta Mol Basis Dis; 2021 Jul; 1867(7):166151. PubMed ID: 33892077
[TBL] [Abstract][Full Text] [Related]
37. Recruitment of miR-8080 by luteolin inhibits androgen receptor splice variant 7 expression in castration-resistant prostate cancer.
Naiki-Ito A; Naiki T; Kato H; Iida K; Etani T; Nagayasu Y; Suzuki S; Yamashita Y; Inaguma S; Onishi M; Tanaka Y; Yasui T; Takahashi S
Carcinogenesis; 2020 Aug; 41(8):1145-1157. PubMed ID: 31805186
[TBL] [Abstract][Full Text] [Related]
38. Role of WNT7B-induced noncanonical pathway in advanced prostate cancer.
Zheng D; Decker KF; Zhou T; Chen J; Qi Z; Jacobs K; Weilbaecher KN; Corey E; Long F; Jia L
Mol Cancer Res; 2013 May; 11(5):482-93. PubMed ID: 23386686
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of hedgehog and androgen receptor signaling pathways produced synergistic suppression of castration-resistant prostate cancer progression.
Gowda PS; Deng JD; Mishra S; Bandyopadhyay A; Liang S; Lin S; Mahalingam D; Sun LZ
Mol Cancer Res; 2013 Nov; 11(11):1448-61. PubMed ID: 23989930
[TBL] [Abstract][Full Text] [Related]
40. Enhancement of anticancer activity of docetaxel by combination with Fuzheng Yiliu decoction in a mouse model of castration-resistant prostate cancer.
Fu W; Hong Z; You X; Din J; Chen B; Zhao B; Yuan G; Li Q
Biomed Pharmacother; 2019 Oct; 118():109374. PubMed ID: 31545228
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
